Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital chlamydia trachomatis infection: A randomized, double-blind, double-dummy, active-controlled, multicenter trial

Clinical Infectious Diseases

Volumn 55, Issue 1, 2012, Pages 82-88

  Geisler, William M ^a   Koltun, William D ^b   Abdelsayed, Nader ^c   Burigo, John ^d   Mena, Leandro ^e   Taylor, Stephanie N ^f   Batteiger, Byron E ^g   Thurman, Andrea R ^h   Hook, Edward W ^a,i   Vaughn, Toby A ^j   Annett, Miriam P ^j   Muenzen, Ruth A ^j   Caminis, John ^j  

^a University of Alabama at Birmingham   (United States)

^b Medical Center for Clinical Research   (United States)

^c Centennial Hills OB/GYN Associates   (United States)

^d OB/GYN Specialists of the Palm Beaches   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

ⁱ Jefferson County Department of Health   (United States)

^j Warner Chilcott Pharmaceuticals Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; DOXYCYCLINE HYCLATE; UNCLASSIFIED DRUG; WC 2031;

ABDOMINAL PAIN; ADULT; CANDIDIASIS; CHLAMYDIAL URETHRITIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MULTICENTER STUDY; NAUSEA AND VOMITING; NUCLEIC ACID AMPLIFICATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; VULVOVAGINAL DISEASE;

ADULT; ANTI-BACTERIAL AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DOXYCYCLINE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84862219188     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis291     Document Type: Review

References (10)

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2009. Atlanta, Georgia: US Department of Health and Human Services; 2010.
2. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, 2010. MMWR 2010; 59(RR-12):44-7.
3. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transm Dis 2002; 29:497-502.
4. Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676-85.
5. Batteiger BE, Tu W, Ofner S, et al. Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201:42-51.
6. Schwebke JR, Rompalo A, Taylor S, et al. Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens-a randomized clinical trial. Clin Infect Dis 2011; 52:163-70.
7. Bachmann LH, Stephens J, Richey CM, Hook EW 3rd. Measured versus self-reported compliance with doxycycline therapy for chlamydia-associated syndromes: high therapeutic success rates despite poor compliance. Sex Transm Dis 1999; 26:272-8.
8. Hillis SD, Coles FB, Litchfield B, Black CM, Mojica B, Schmitt D. Doxycycline and azithromycin for prevention of chlamydial persistence of recurrence one month after treatment in women: a use-effectiveness study in public health settings. Sex Transm Dis 1998; 25: 5-11.
9. Rogers SM, Miller WC, Turner CF, et al. Concordance of Chlamydia trachomatis infections within sexual partnerships. Sex Transm Infect 2008; 84:23-8.
10. Geisler WM. Duration of untreated uncomplicated genital Chlamydia trachomatis infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis 2010; 201:S104-13.